EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s12282-020-01166-0.pdf
Reference61 articles.
1. Chang M. Tamoxifen resistance in breast cancer. Biomol Ther. 2012;20(3):256–67. https://doi.org/10.4062/biomolther.2012.20.3.256.
2. Hu Q, Baeg GH. Role of epigenome in tumorigenesis and drug resistance. Food Chem Toxicol. 2017;109(Pt 1):663–8. https://doi.org/10.1016/j.fct.2017.07.022.
3. Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol. 2004;191(5):1552–72. https://doi.org/10.1016/j.ajog.2004.05.025.
4. Askarian-Amiri ME, Leung E, Finlay G, Baguley BC. The regulatory role of long noncoding RNAs in cancer drug resistance. Methods Mol Biol. 2016;1395:207–27. https://doi.org/10.1007/978-1-4939-3347-1_12.
5. Rueff J, Rodrigues AS. Cancer drug resistance: a brief overview from a genetic viewpoint. Methods Mol Biol. 2016;1395:1–18. https://doi.org/10.1007/978-1-4939-3347-1_1.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Recent Contributions of Mass Spectrometry-Based “Omics” in the Studies of Breast Cancer;Chemical Research in Toxicology;2023-11-27
2. Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects;Epigenomics;2022-11
3. Role of β1‐integrin in promoting cell motility and tamoxifen resistance of human breast cancer MCF‐7 cells;Asia-Pacific Journal of Clinical Oncology;2022-09-05
4. EZH2 Protein Expression in Estrogen Receptor Positive Invasive Breast Cancer Treated With Neoadjuvant Endocrine Therapy: An Exploratory Study of Association With Tumor Response;Applied Immunohistochemistry & Molecular Morphology;2022-09-02
5. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells;Cancer Letters;2021-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3